Vetoquinol

VETO.PA

Lure, France· Est. 1933

vetoquinol.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

VETO.PA · Stock Price

EUR 75.70+2.80 (+3.84%)

Market Cap: $1.0B

Historical price data

Overview

Vetoquinol's mission is to advance animal health through applied veterinary science, serving as a trusted, independent partner to veterinarians, farmers, and pet owners worldwide. The company has achieved steady growth, with €545 million in 2023 sales, by focusing on formulation innovation, lifecycle management, and geographic expansion. Its strategy is built on three pillars: maintaining independence from Big Pharma, controlling a vertically integrated value chain from R&D to manufacturing, and cultivating deep, direct relationships with the veterinary community.

Companion Animal HealthLivestock Health

Technology Platform

Applied veterinary R&D and advanced formulation science, specializing in innovative drug delivery systems (transdermal, long-acting injectables, palatable orals), fixed-dose combinations, and lifecycle management of pharmaceutical compounds.

Funding History

IPOUndisclosedUndisclosedJun 30, 2006

Opportunities

Vetoquinol is poised to capitalize on the humanization of pets, driving demand for advanced companion animal therapeutics, and the global shift toward sustainable livestock production, requiring alternatives to antibiotics and zinc oxide.

Geographic expansion into high-growth emerging markets provides a significant additional growth vector.

Risk Factors

Key risks include intense competition from larger animal health conglomerates, regulatory complexities and potential bans on key ingredients, supply chain concentration, and economic sensitivity in the livestock segment.

Execution risk on its high-potential pipeline, notably Zeleris, is also a factor.

Competitive Landscape

Vetoquinol competes in a consolidated market dominated by Zoetis, Merck, Boehringer Ingelheim, and Elanco. Its strategy is not scale-based but focuses on independence, vertical integration, and deep veterinary relationships to compete effectively in targeted therapeutic niches against both giants and mid-tier peers like Virbac and Ceva.